EU regulator OKs Pfizer vaccine booster for 18 and older

The European Union’s drug regulator has given its backing to booster shots of the Pfizer-BioNTech COVID-19 vaccine for people 18 and older

Via AP news wire
Monday 04 October 2021 16:10

The European Union’s drug regulator gave its backing Monday to administering booster shots of the Pfizer-BioNTech COVID-19 vaccine for people 18 and older.

The European Medicines Agency said the booster doses “may be considered at least 6 months after the second dose for people aged 18 years and older.”

The agency’s human medicines committee issued the recommendation after studying data for the Pfizer vaccine that showed a rise in antibody levels following boosters given around 6 months after the second dose in people from 18 to 55 years old.

The agency also said it supports giving a third dose of either the Pfizer-BioNTech or the Moderna vaccine to people with severely weakened immune systems at least 28 days after their second shot.

The agency said its decision came after studies showed that an extra dose of the vaccines increased people's ability to produce antibodies against the virus that causes COVID-19 in organ transplant patients with weakened immune systems.

“Although there is no direct evidence that the ability to produce antibodies in these patients protected against COVID-19, it is expected that the extra dose would increase protection at least in some patients,” the agency said in a statement.

The recommendations go to health authorities in all 27 EU nations. Some countries already have begun administering booster shots.

Numerous studies have shown that the Pfizer-BioNTech and Moderna vaccines remain strongly protective months after people receive their second dose, dramatically cutting the risk of hospitalization and death.

The World Health Organization s chief had urged wealthy nations not to use booster doses this year, saying there is no scientific data that proves the shots are necessary. He said COVID-19 vaccines would be put to better use in developing countries, where many people still have not received their first vaccine shots.

The United States government launched a campaign last month to offer boosters of Pfizer’s COVID-19 vaccine to millions of Americans even as federal health officials stressed the real problem remains getting first shots to the unvaccinated.

The coronavirus pandemic has killed at least 4.8 million people around the world.

___

Follow all AP stories on the coronavirus pandemic at https://apnews.com/hub/coronavirus-pandemic.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Please enter a valid email
Please enter a valid email
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Please enter your first name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
Please enter your last name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
You must be over 18 years old to register
You must be over 18 years old to register
Opt-out-policy
You can opt-out at any time by signing in to your account to manage your preferences. Each email has a link to unsubscribe.

By clicking ‘Create my account’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in